Please share...
LONDON (Reuters) – Commercial rather than technical hurdles ultimately torpedoed Novo Nordisk’s bid to make an oral form of insulin, its chief executive said on Wednesday, underscoring the impact of U.S. price pressure on the world’s top insulin supplier.
